Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05417711

Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus

This clinical study is a prospective, multicenter, randomized, controlled, double-blind clinical study. Sun Yat Sen Memorial Hospital of Sun Yat sen University was the central unit, and Nanjing First Hospital, Sun Yat Sen people's Hospital, Guanfzhou Panyu central Hospital and Zhuhai integrated traditional Chinese and Western medicine hospital were the cooperative units. In this study, 388 patients with chronic subjective tinnitus were recruited. In view of chronic subjective tinnitus, a common ear disease, the study gave the patients three months of treatment with transcutaneous vagus nerve stimulation paired with tailor-made notched music therapy or tailor-made notched music training alone. By comparing the changes of subjective scale scores related to tinnitus before and after treatment in patients receiving two different therapies, such as THI, VAS, BAI, BDI, PSQI, to evaluate the efficacy of the two therapies, so as to judge whether transcutaneous vagus nerve stimulation paired with tailor-made notched music therapy is better than tailor-made notched music training alone. In addition, the study will continue to follow up the patients after the treatment for one year to observe the difference in the long-term sustained efficacy of the two therapies. This clinical study will also evaluate the two therapies from the perspective of compliance and safety, and explore the factors that affect the efficacy of the two therapies.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Unified rules for filling in case report forms:

  • All case report forms must be completed by designated and trained researchers.
  • Two data managers independently input and proofread the data in duplicate.
  • The data manager will modify, confirm and enter the data according to the scales written by participant.
  • The locked data file will not be changed.
  • Use medical terms / concepts to record AES . The type, degree, occurrence time, duration, treatment measures and treatment process shall be recorded in detail.

Sample size estimation:

  • △ THI≥ 7 points in the comparison between groups indicates that the difference in efficacy has clinical significance, the superiority margin is established.
  • The pre-test results showed that △ THI = -10.2 points, SD = 10.0 points in the two groups after the treatment.
  • According to unilateral inspection standard α= 0.025, inspection efficacy 1- β= 0.80, using two sample t-test to estimate the sample size, the results show that at least 155 subjects are included in each group.
  • Further estimation was made according to the loss of follow-up rate of 20%. Finally, at least 194 subjects (388 persons in total) should be included in each group.
  • PASS 21.0.03 (NCSs, LLC, Kaysville, Utah, USA) is adopted for the above calculation.

Plan for missing data:

  • If the subject uses the drugs, treatment or surgery prohibited in the protocol, the subject will no longer meet the conditions of the clinical study and will be deemed to have withdrawn from the study.
  • If the event occurs before 3 months of treatment, the subject's data will no longer be used for statistical analysis of subsequent data.
  • If the event occurs in the follow-up period after the completion of treatment, the data of the subject before and after treatment shall be retained. The data in the follow-up period shall be regarded as missing data and filled with corresponding methods for full analysis set analysis.
  • For the missing data caused by the loss of follow-up, this study will use the method of multiple imputation to estimate the missing value.
  • The research subjects who failed in screening will provide corresponding treatment according to their own conditions and clinical guidelines. These subjects will not be included in the clinical study.

Statistical analysis plan:

When considering the influence of baseline, the continuous variables were analyzed by covariance analysis, and the qualitative indicators were tested by CMH test or logistic regression.

Primary analysis: Using covariance analysis to compare the different changes of THI scores between two groups after 3-month treatment, controlled for age and baseline THI.

Secondary analysis: Using covariance analysis to compare the different changes of VAS, BAI, BDI, PSQI scores between two groups after 3-month treatment, controlled for age and baseline values corresponding to each scale.

Using a repeated measure ANOVA to compare the different changes of THI, VAS, BAI, BDI, PSQI between two groups at 3, 6 and 12 follow-up visits.

Using Chi square test or Fisher exact test to compare the different efficient rate between two groups after 3-month treatment.

Exploratory analysis:

Using multiple linear regression analysis to explore the factors affecting the short-term and long -term efficacy of the two treatments, such as age, hearing loss threshold, tinnitus loudness, tinnitus frequency and so on.

Using Independent two sample t-test or nonparametric analysis to compare the differences in EEG- or fMRI-related indicators between two groups.

Safety analysis:

Using Pearson's chi-square test to compare the difference of adverse event incidence rate between two groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with tinnitus as the main complaint: the patients subjectively feel the sound in the ear or deep part of the head without internal or external sound stimulation, and therefore seek medical treatment
  • Chronic (≥ 6 months) and tonal tinnitus
  • Age 18-60
  • Tinnitus frequency is 125-8000 Hz
  • Hearing threshold at each frequency shall not exceed 70 dB HL

Exclusion criteria

  • Patients with conductive deafness, history of middle ear surgery, pulsatile tinnitus caused by vascular distortion and tinnitus caused by Meniere disease
  • History of head trauma, central nervous system diseases, mental diseases and drug abuse

Treatment and study plan

Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy

Device

The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.

Tailor-made Notched Music Training

Device

Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.

Primary outcomes

  1. Changes in Tinnitus Handicap Inventory (THI) scores for short-term efficacy assessment

    Time frame: From baseline to 3-month follow-up visit

    Difference in the change of THI scores between two groups after 3-month treatment. The THI evaluates the severity of tinnitus in terms of emotion and function. The global scores of THI range from 0 (no disability) to 100 (serve disability).

Secondary outcomes

  1. Changes in scores of Visual Analog Scale (VAS) for short-term efficacy assessment

    Time frame: From baseline to 3-month follow-up visit

    Difference in the change of VAS scores between two groups after 3-month treatment. The total VAS scores range from 0 (negligible) to 10 (too nosiy to tolerate), reflecting the loudness of tinnitus patients feel.

  2. Changes in scores of Beck Anxiety Inventory (BAI) for short-term efficacy assessment

    Time frame: From baseline to 3-month follow-up visit

    Difference in the change of BAI scores between two groups after 3-month treatment. The total BAI scores range from 0 (normal) to 63 (serve anxiety), reflecting the degree of anxiety.

  3. Changes in scores of Beck Depression Inventory (BDI) for short-term efficacy assessment

    Time frame: From baseline to 3-month follow-up visit

    Difference in the change of BDI scores between two groups after 3-month treatment. The total BDI scores range from 0 (normal) to 63 (serve depression), reflecting the degree of depression.

  4. Changes in scores of Pittsburgh sleep quality index (PSQI) for short-term efficacy assessment

    Time frame: From baseline to 3-month follow-up visit

    Difference in the change of PSQI scores between two groups after 3-month treatment. The total PSQI scores range from 0 (sleep well) to 21 (quite poor sleep), reflecting the sleep quality.

  5. Changes of Tinnitus Handicap Inventory (THI) scores in the two groups for long-term efficacy assessment

    Time frame: From 3-month follow-up visit to 12-month follow-up visit

    Difference in changes of THI between two groups from 3-month follow-up visit to 12-month follow-up visit. The THI evaluates the severity of tinnitus in terms of emotion and function. The global scores of THI range from 0 (no disability) to 100 (serve disability).

  6. Changes of Visual Analog Scale (VAS) scores in the two groups for long-term efficacy assessment

    Time frame: From 3-month follow-up visit to 12-month follow-up visit

    Difference in changes of VAS between two groups from 3-month follow-up visit to 12-month follow-up visit. The total VAS scores range from 0 (negligible) to 10 (too nosiy to tolerate), reflecting the loudness of tinnitus patients feel.

  7. Changes of Beck Anxiety Inventory (BAI) scores in the two groups for long-term efficacy assessment

    Time frame: From 3-month follow-up visit to 12-month follow-up visit

    Difference in changes of BAI between two groups from 3-month follow-up visit to 12-month follow-up visit. The total BAI scores range from 0 (normal) to 63 (serve anxiety), reflecting the degree of anxiety.

  8. Changes of Beck Depression Inventory (BDI) scores in the two groups for long-term efficacy assessment

    Time frame: From 3-month follow-up visit to 12-month follow-up visit

    Difference in changes of PSQI between two groups from 3-month follow-up visit to 12-month follow-up visit. The total BDI scores range from 0 (normal) to 63 (serve depression), reflecting the degree of depression.

  9. Changes of Pittsburgh sleep quality index (PSQI) scores in the two groups for long-term efficacy assessment

    Time frame: From 3-month follow-up visit to 12-month follow-up visit

    Difference in changes of PSQI between two groups from 3-month follow-up visit to 12-month follow-up visit. The total PSQI scores range from 0 (sleep well) to 21 (quite poor sleep), reflecting the sleep quality.

  10. The effective rate of relieving chronic subjective tinnitus in the two groups

    Time frame: From baseline to 3-month follow-up visit

    Group effective rate = number of patients in each group who completed 3 months of treatment and whose THI score decreased by ≥ 7 points / number of patients in each group who completed 3 months of treatment.

  11. The difference of functional connectivity based on resting state electroencephalogram (EEG) between the two groups

    Time frame: From baseline to 12-month follow-up visit

    The difference of functional connectivity based on resting state electroencephalogram (EEG) in the two groups from baseline to 12-month follow-up visit. The functional connectivity is defined as the correlation between two different brain regions based on coherence or phase synchronization.

  12. The difference of effective connectivity based on resting state electroencephalogram (EEG) between the two groups

    Time frame: From baseline to 12-month follow-up visit

    The difference of effective connectivity based on resting state electroencephalogram (EEG) in the two groups from baseline to 12-month follow-up visit. The effective connectivity is defined as the directed functional connectivity between two brain regions based on granger causality analysis.

  13. The difference of functional connectivity based on functional magnetic resonance imaging (fMRI) between the two groups

    Time frame: From baseline to 12-month follow-up visit

    The difference of functional connectivity based on functional magnetic resonance imaging (fMRI) in the two groups from baseline to 12-month follow-up visit. The functional connectivity is defined as the Pearson's correlation between two different brain regions.

  14. The difference of effective connectivity based on functional magnetic resonance imaging (fMRI) between the two groups

    Time frame: From baseline to 12-month follow-up visit

    The difference of effective connectivity based on functional magnetic resonance imaging (fMRI) in the two groups from baseline to 12-month follow-up visit. The effective connectivity is defined as the directed functional connectivity between two brain regions based on granger causality analysis.

Other outcomes

  1. Incidence of treatment-related adverse events

    Time frame: From baseline to 12-month follow-up visit

    Treatment related adverse events in two groups include: auditory system related adverse reactions caused by treatment, such as auricle burn, earache, hearing loss, tinnitus aggravation, and head injury Dizziness, headache, palpitation, vomiting and other non auditory system related adverse reactions. Incidence of adverse events = number of treatment-related adverse events during treatment / total number of participants in treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Yuexin Cai Cai, Doctor

CONTACT

[email protected]

+8613825063663

Zhaopeng Tong Tong, bachelor

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Other

Collaborators

  • Affiliated Zhuhai Hospital of Southern Medical University
  • Eighth Affiliated Hospital, Sun Yat-sen University
  • Guangzhou Panyu Central Hospital
  • Second Affiliated Hospital of Guangzhou Medical University
  • Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University
  • Southern Medical University, China
  • The First Affiliated Hospital with Nanjing Medical University
  • Zhongshan People's Hospital, Guangdong, China

Registry information

Official study title

Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jun 14, 2022
Registry last updated
Nov 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.